An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study

Name: An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study
Published: 2021
License: Public Domain

Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

crohn disease, ustekinumab, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study

Related documents